The credit facility, available through Sept. 17, 2024, replaces a prior credit facility dated Aug. 11, 2016 for $1 billion.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.
While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.
The genetic disease risk test, which covers 59 genes endorsed by ACMG, is offered through the Helix marketplace and includes genetic counseling services.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.